Citations

Clear

9383 citation(s) found for "Thomas, PS".

Treatment of Children and Adults With X-Linked Hypophosphatemia With Calcitriol Alone: A Prospective, Open-Label Study
Jordan, Mackenzie, Gehman, Sarah, Rudolph, Sara , Jüppner, Harald , Thacher, Thomas, Lee, Hang , Gee, Michael S. , Pierce, Theodore T. , Ceglia, Lisa, Bouxsein, Mary , Demay, Marie B. , Liu, Eva S. , Lee, Hang , Ceglia, Lisa , Liu, Eva S , Mitchell, Deborah M. , Misra, Madhusmita , Thacher, Thomas, Gee, Michael Stanley

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | October 23, 2025 | Volume: 111 | Issue: 4 | Pages: e1037-e1049

10.1210/clinem/dgaf585 | PMID 41137448 Get It

Abstract Context Preclinical studies demonstrate that treatment with calcitriol attenuates skeletal complications in mice with X-linked hypophosphatemia (XLH). Objective This work aimed to assess serum markers of mineral metabolism, nephrocalcinosis, skeletal microarchitecture, growth, and evidence of rickets following calcitriol monotherapy in children and adults with XLH. Methods A 1-year, prospective, single-arm, open-label study was conducted comparing baseline and 12-month outcomes. Participants were recruited from outpatient endocrinology clinics in the United States. Data were collected in a research unit. Eligible participants were aged 4 years or older, not pregnant, with baseline 25-hydroxyvitamin D of 20 ng/mL or greater and normal serum calcium. Participants were treated with calcitriol, with dose based on serum and urinary calcium concentrations, for 1 year. The primary end points were change in serum phosphate and nephrocalcinosis (all participants) and rickets severity score (children). Secondary end points included changes in additional markers of mineral metabolism, skeletal microarchitecture parameters via high-resolution peripheral quantitative computed tomography (all participants), and height z-scores (children). Results Serum phosphate did not change over 12 months of optimized calcitriol treatment. Rickets improved in 2 of 4 children with open epiphyses; height z-scores were unchanged. Nephrocalcinosis scores remained stable. Adults had increased cortical thickness at the radius diaphysis (P = .012). Serum alkaline phosphatase decreased in children (P = .021) and parathyroid hormone trended lower both in children (P = .065) and adults (P = .063). Four participants developed mild hypercalcemia and 2 developed hypercalciuria that resolved with calcitriol titration. Conclusion Calcitriol monotherapy is safe and well-tolerated in XLH, with modest benefits on laboratory indices of mineral metabolism and rickets.
#2139 Renal uric acid microcrystals drive hyperinflammation, cystogenesis and disease progression in ADPKD
Strubl, Sebastian , Holznecht, Nickolas J., Aceves, Brina A., Schimmel, Meg, Koestner, Stella, Grundmann, Franziska , Mueller, Roman-Ulrich, Antczak, Philipp , Torres, Jacob A. , Schimmel, Meg, Alkarkoukly, Samer , Harris, Peter C. , Mueller, Roman-Ulrich, Weimbs, Thomas

Mayo Clinic

Nephrology Dialysis Transplantation | October 22, 2025 | Volume: 40 | Issue: Supplement_3 | Pages: No page available

10.1093/ndt/gfaf116.0167 Get It

Abstract Background and Aims Patients with ADPKD exhibit an increased prevalence of kidney stones with a significant overrepresentation of uric acid (UA) stones which has led to the previous suggestion that UA may be associated with disease progression in ADPKD. However, available results are controversial and the exact mechanism remains unknown. Since we have previously reported that calcium-based microcrystals worsen ADPKD disease progression we hypothesized that renal UA crystallization could affect PKD disease progression and aimed to investigate this in animal models of PKD and the AD(H)PKD registry at the University Hospital Cologne. Method WT and Pkd1+/− rats were supplemented with UA and the uricase inhibitor oxonic acid from 8 to 10 weeks of age to induce moderate hyperuricemia causing renal UA crystal deposition. This was followed by washout from 10 to 18 weeks to analyze crystal clearance. For additional treatment with the ketone beta-hydroxybutyrate (BHB) and alkaline Citrate, adult rats received a solution containing 2.1% BHB and 13.75 mM tripotassium citrate/16.75 mM citric acid in the drinking water from 14 to 18 weeks of age. Human data including eGFR, UA levels in serum, spot urine and 24-hour urine and urine pH were used from the AD(H)PKD study (Clinical Trials ID: NCT02497521) and analyzed using multivariable linear models. Results UA crystal deposition in Pkd1+/− rats led to significantly increased kidney growth, tubule dilation and UA crystal burden compared to UA-treated WT controls. Dilated tubules exhibited strong TLR-4 expression, NLRP3 activation, recruitment of peritubular macrophages and intraluminal neutrophils undergoing NETosis. Strikingly—although untreated heterozygous Pkd1+/− rats fail to develop a polycystic phenotype—UA-treated Pkd1+/− rats developed polycystic kidney disease after 8 weeks washout period with persistent activation of TLR4, NLRP3, pericystic macrophages and intracystic neutrophils. UA-treated WT rats displayed a normalization of renal tubules. Previously, we demonstrated that treatment with BHB and Citrate can ameliorate PKD disease progression. BHB has been reported to inhibit TLR4-NLRP3 signaling and citrate can prevent UA deposition due to urine alkalinization. Therefore, we induced UA crystal deposition in Pkd1+/− followed by 4 weeks of normal diet to allow crystal clearance, followed by treatment with BHB/Citrate in the drinking water. Remarkably, BHB/Citrate potently inhibited the progression to PKD in Pkd1+/− rats by ameliorating cyst growth, TLR4-NLRP3 activation, and macrophage and neutrophil recruitment. Translational analysis of UA stone forming parameters in the AD(H)PKD patient registry showed a correlation of serum and urine UA concentration with eGFR slope. However, significance of this association was lost after adjusting for eGFR, age and sex. In contrast, analysis of the Marshal lithogenic risk score which combines urine UA with urine pH to predict the risk for UA crystal/stone formation showed a significant and independent impact on eGFR slope. Conclusion Our results suggest that UA exposure is a sufficient environmental hit to induce cystogenesis in a heterozygous Pkd1 rat model. A heterozygous Pkd1 gene mutation as observed in ADPKD patients creates a hyperresponsive renal phenotype upon UA crystal formation leading to exaggerated tubule dilation, persistent inflammation, fibrosis and progression to PKD. Treatment with BHB/Citrate significantly reduces TLR4-NLRP3 activation and macrophage/ neutrophil recruitment leading to a significant amelioration of UA-induced cystogenesis. We conclude that UA crystal deposition could accelerate PKD disease progression by NLRP3-mediated and macrophage/neutrophil-based hyperinflammation. BHB/Citrate could not only prevent UA crystallization but ameliorate UA-associated kidney injury and ADPKD disease progression. Finally, the translational analysis in the AD(H)PKD patient registry suggest that, although not showing serum uric acid as independent risk factor, the lithogenic risk- largely driven by the combination of urine uric acid and urine pH- could be a driver of PKD disease progression.
Examining Countermovement Jump Performance and Dynamic Balance Among Male High School Athletes With Varying Levels of Sports Specialization
VanZile, Adam W., Jones, Daniel D., McHugh, Lydia J., Clickovich, Gracie L., Morales, Marissa A., Reimschisel, Ryan K., Widenhoefer, Tricia L., Baughman, Jacqueline T., Urquidi, Mario D., Conner, Dylan J., Dobbs, Ward C. , Luedke, Joel, Luedke, Joel A, Jones, Daniel D., Morales, Marissa A., Jagim, Andrew R. , Almonroeder, Thomas Gus

Mayo Clinic

Journal of Strength & Conditioning Research | October 21, 2025 | Volume: 39 | Issue: 11 | Pages: 1163-1168

10.1519/jsc.0000000000005200 | PMID 40644664 Get It

Abstract VanZile, AW, Jones, DD, McHugh, LJ, Clickovich, GL, Morales, MA, Reimschisel, RK, Widenhoefer, TL, Baughman, JT, Urquidi, MD, Conner, DJ, Dobbs, WC, Jagim, AR, Luedke, JA, and Almonroeder, TG. Examining countermovement jump performance and dynamic balance among male high school athletes with varying levels of sports specialization. J Strength Cond Res 39(11): 1163–1168, 2025—Specializing at a young age may limit an athlete's motor development, since focusing on a single sport potentially exposes athletes to less variety of movements and neuromuscular demands. However, there are few studies examining the association between sport specialization and movement performance/control. The purpose of this study was to compare countermovement jump performance and dynamic balance among high school athletes of varying levels of sports specialization. 110 male high school athletes completed countermovement jump testing and the Y-Balance Test (YBT). Ground reaction forces were recorded during countermovement jumps and used to derive peak force, peak velocity, peak power, jump height, and the modified reactive strength index. Y-Balance Test composite scores were calculated to assess dynamic balance across multiple directions, for the dominant and non-dominant limbs. Athletes were grouped into high ( n = 46), moderate ( n = 39), and low ( n = 25) specialization groups based on their sport participation habits. There were no between-group differences for any of the countermovement jump metrics ( p > 0.05). For the YBT composite scores, there was not a group-by-limb interaction effect ( p = 0.28); however, there was a main effect of group ( p = 0.03). Post hoc tests indicated that the high specialization group exhibited lower YBT composite scores compared to the moderate specialization group ( p = 0.01) and a trend toward lower scores compared to the low specialization group ( p = 0.05). In general, highly specialized male athletes exhibited poorer dynamic balance compared to less specialized athletes.
Standalone Endovascular Embolization versus Stereotactic Radiosurgery in the Treatment of Arteriovenous Malformations in Eloquent Brain
Musmar, Basel , Abdalrazeq, Hammam , Adeeb, Nimer , Salim, Hamza , Roy, Joanna M. , Aslan, Assala , Tjoumakaris, Stavropoula I., Ogilvy, Christopher S. , Başkaya, Mustafa K. , Kondziolka, Douglas, Sheehan, Jason P. , Riina, Howard A. , Abushehab, Abdallah, Naamani, Kareem El, Ironside, Natasha , Gummadi, Sanjeev, Ataoglu, Cagdas , Muram, Sandeep , Sconzo, Daniel , Rezai, Arwin, Alwakaa, Omar , Park, Min S. , Hanalıoğlu, Şahin , Erginoğlu, Ufuk , Sen, Rajeev , Burkhardt, Jan‐Karl , Starke, Robert M. , Sekhar, Laligam N., Altschul, David , Haranhalli, Neil , McAvoy, Malia , Zeineddine, Hussein A. , Atallah, Elias , Rosenwasser, Robert H. , Stapleton, Christopher J. , Koch, Matthew J. , Srinivasan, Visish M. , Bulsara, Ketan R., Kim, Louis J. , Pukenas, Bryan, Smith, Edward R. , Alaraj, Ali , Patel, Aman B. , Notarianni, Christina , Lawton, Michael, Guthikonda, Bharat , Salim, Hamza , Riina, Howard , Dmytriw, Adam A , Gummadi, Sanjeev , Ataoglu, Cagdas , Essibayi, Muhammed Amir , Keles, Abdullah , Muram, Sandeep , Alwakaa, Omar , Mantziaris, Georgios , Park, Min S , Hanalioglu, Sahin , Erginoglu, Ufuk , Pöppe, Johannes , Griessenauer, Christoph J , Starke, Robert M , Levitt, Michael R , Altschul, David J , Haranhalli, Neil , Zeineddine, Hussein A , Atallah, Elias , Stapleton, Christopher , Koch, Matthew J , Srinivasan, Visish M , Chen, Peng R , Blackburn, Spiros , Bulsara, Ketan , Choudhri, Omar , Pukenas, Bryan , Smith, Edward , Alaraj, Ali , Patel, Aman B , Notarianni, Christina , Jabbour, Pascal , Musmar, Basel , Ogilvy, Christopher S , Tjoumakaris, Stavropoula , Kandregula, Sandeep , Dmytriw, Adam A. , Naamani, Kareem El , Abdelsalam, Ahmed , Kumbhare, Deepak , Essibayi, Muhammed Amir , Keleş, Abdullah , Tos, Salem M , Mantziaris, Georgios , Sen, Rajeev D., Griessenauer, Christoph J. , Sekhar, Laligam N. , Levitt, Michael R. , Abla, Adib A. , Gooch, Michael Reid , Kim, Louis J. , Choudhri, Omar , Pukenas, Bryan , Mosimann, Pascal J , Aziz‐Sultan, Mohammad Ali , Savardekar, Amey Rajan , Cuellar, Hugo , Morcos, Jacques J. , Jabbour, Pascal

Mayo Clinic

Radiology | October 21, 2025 | Volume: 317 | Issue: 1 | Pages: No page available

10.1148/radiol.250329 | PMID 41117652 Get It

Stereotactic radiosurgery was associated with a higher obliteration rate compared with embolization in patients with eloquent brain arteriovenous malformations, whereas there was no evidence of a difference in functional outcomes or complications after adjustment.
International Headache society evidence-based guidelines on the use of non-invasive neuromodulation devices for the acute and preventive treatment of migraine
Yuan, Hsiangkuo , Orr, Serena L. , Al‐Karagholi, Mohammad Al‐Mahdi , Ashina, Messoud , Cohen, Fred , Diener, Hans‐Christoph , Marmura, Michael J. , Martinelli, Daniele , Matharu, Manjit , Simmonds, Lucy , Tassorelli, Cristina , Tepper, Stewart J. , Al-Karagholi, Mohammad A M , Marmura, Michael J , Martinelli, Daniele , Matharu, Manjit Singh , Petersen, Anja S , Pozo-Rosich, Patricia , Sacco, Simona , Simmonds, Lucy , Tassorelli, Cristina , Terwindt, Gisela , Wang, Shuu-Jiun , Yeh, Jiunn-Tyng , Silberstein, Stephan D , Diener, Hans-Christoph , Ashina, Messoud , Yuan, Hsiangkuo , Dodick, David W. , Jensen, Rigmor , Pozo‐Rosich, Patricia , Sacco, Simona , Terwindt, Gisela M. , Wang, Shuu‐Jiun , Silberstein, Stephen D.

Mayo Clinic

Cephalalgia | October 21, 2025 | Volume: 45 | Issue: 10 | Pages: No page available

10.1177/03331024251388377 | PMID 41117312 Get It

Objective To develop evidence-based clinical practice guidelines for non-invasive neuromodulation devices in acute and preventive migraine treatment. Methods A systematic review was conducted across six databases from 1946 to April 2025. Randomized controlled trials evaluating Food and Drug Administration-cleared or Conformité Européenne (CE)-marked non-invasive neuromodulation devices were included. The quality of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology, and recommendations were developed through consensus following GRADE Evidence-to-Decision frameworks. The working group comprised 15 senior members and six junior members. Results From 1536 initial records, 15 studies met the inclusion criteria and were finally used to develop evidence-based recommendations. Evidence quality ranged from very low to moderate. Weak recommendations were issued for SAVI Dual, Cefaly, Relivion, and Nerivio in the treatment of acute migraine attacks, and for gammaCore Sapphire, Cefaly, and Nerivio in the preventive migraine treatment. Other cleared devices received no recommendations or have no eligible studies for the GRADE assessment. The primary limitations across studies included imprecision due to small sample sizes and various methodological concerns. Additionally, expert consensus recommendations were developed for devices and clinical scenarios not adequately covered by randomized controlled trials, including potential applications in pediatric populations, vestibular migraine, chronic migraine, menstrual migraine, and medication overuse headache. Conclusion Non-invasive neuromodulation devices offer promising alternatives to drug treatment for migraine management. These devices are safe and generally well tolerated and devoid of drug interactions. While current evidence quality varies, ongoing research and technological advancements show encouraging potential. Future studies should adhere to International Headache Society guidelines for neuromodulation device trials, address proper sham controls and blinding assessment, and account for patient adherence challenges in device use. Expanded insurance coverage would enhance cost-effectiveness and device accessibility. These guidelines provide a framework for clinical decision-making while highlighting areas requiring further research.
Migraine-related disability according to headache frequency subclassifications: A systematic review and meta-analysis
Matharu, Manjit , Silberstein, Stephen D. , Yuan, Hsiangkuo , Edgar, Deborah , Schwedt, Todd J. , Obermann, Mark , Matharu, Manjit Singh , Silberstein, Stephan D , Schwedt, Todd J , Yuan, Hsiangkuo , Colman, Roos , Lantéri‐Minet, Michel

Mayo Clinic

Cephalalgia | October 17, 2025 | Volume: 45 | Issue: 10 | Pages: No page available

10.1177/03331024251385965 | PMID 41105531 Get It

Background This systematic review and meta-analysis synthesized migraine-related disability outcomes according to headache frequency subclassifications, including low-frequency episodic migraine (LFEM), high-frequency episodic migraine (HFEM) and chronic migraine (CM). Methods We searched the PubMed and Cochrane Library (CENTRAL) up to 16 October 2024 for peer-reviewed non-interventional studies reporting migraine-related disability outcomes in CM and subclassifications of episodic migraine (e.g. LFEM and HFEM). Eligible studies with an HFEM subgroup were grouped by headache frequency measure (monthly migraine days [MMD] or monthly headache days [MHD]), HFEM subgroup, disability parameter and study setting. Random-effects meta-analyses were conducted on groups with three or more studies, with the results presented in forest plots. Risk of bias was assessed using Joanna Briggs Institute tools. Results Of the 32 included studies, 27 were grouped, yielding five meta-analysis groups containing three or more studies. All five groups had an HFEM subgroup of 8–14 MHD. Accordingly, we classified LFEM as 0–7 MHD and CM as ≥15 MHD. Ten studies contributed data to the five meta-analysis groups. Estimated pooled values are reported by headache frequency subgroup for each meta-analysis group: LFEM (95% confidence interval [CI]), HFEM (95% CI) and CM (95% CI). For meta-analysis group 1, four population-based studies reported Migraine Disability Assessment (MIDAS) Grade IV proportions, with pooled values of 11.1% (7.1–17.1), 43.9% (31.8–56.9) and 57.5% (42.7–71.1), respectively. For meta-analysis group 2, five population-based studies documented Work Productivity and Activity Impairment (WPAI) outcomes. Pooled mean overall work productivity impairment (OWPI) scores were 36.9% (30.8–43.1), 44.7% (38.4–51.0) and 52.0% (47.7–56.3), respectively. Pooled mean activity impairment (AI) scores were 36.4% (33.7–39.1), 46.4% (42.8–50.0) and 53.5% (52.1–54.8), respectively. For meta-analysis group 3, three clinic-based studies presented MIDAS Grade IV proportions. Pooled values were 15.0% (4.4–40.5), 42.4% (17.1–72.4) and 65.7% (30.3–89.4), respectively. For meta-analysis group 4, three clinic-based studies reported WPAI outcomes. Pooled mean OWPI scores were 28.8% (21.6–35.9), 40.2% (36.2–44.2) and 49.6% (46.3–52.9), respectively. Pooled mean AI scores were 29.4% (21.9–36.9), 43.5% (39.0–48.1) and 51.6% (48.8–54.4), respectively. For meta-analysis group 5, three clinic-based studies detailed MIDAS scores. Pooled mean scores were 10.7 (3.9–17.5), 23.9 (9.4–38.4) and 49.6 (15.8–83.3), respectively. Conclusions This study showed a pattern of increasing migraine-related disability with rising headache frequency. Regardless of study setting, our meta-analyses also suggested a severe level of disability in many individuals (42%–44%) with HFEM, highlighting an unmet need for more effective migraine management. Disability burden and headache frequency should both be considered when determining treatment needs and therapy access, particularly for patients with HFEM. Study Registration: INPLASY2024120039.
Outcomes of patent foramen ovale closure in patients over 60 years with cryptogenic stroke: A systematic review and meta-analysis
Jazayeri, Seyed Behnam , Phan, Cattien , Ravichandran, Soumya , Maleki, Ana H., Dumitrașcu, Oana , Agrawal, Kunal , Modir, Royya , Hemmen, Thomas , Poli, Sven , Meyer, Dawn , Meyer, Brett C. , Modir, Royya , Poli, Sven , Meyer, Brett C , Ghozy, Sherief , Agrawal, Kunal, Zuern, Christine S. , Trabattoni, Daniela , Shahripour, Reza Bavarsad , Agrawal, Kush

Mayo Clinic

International Journal of Stroke | October 16, 2025 | Volume: 21 | Issue: 5 | Pages: 603-612

10.1177/17474930251392333 | PMID 41099439 Get It

Background: In younger patients (<60 years) with cryptogenic stroke (CS) presumed to be patent foramen ovale (PFO)-related, the standard approach involves transcatheter PFO closure combined with antithrombotic therapy. However, due to their exclusion from randomized clinical trials (RCTs), no formal recommendations exist for patients ⩾60 years. This study had two objectives (1) to compare the efficacy and safety of PFO closure versus antithrombotic therapy alone (ATA) exclusively in older patients (⩾60 years) and (2) to assess the outcomes of PFO closure in patients ⩾ 60 years versus < 60 years. Methods: We searched PubMed, Embase, Web of Science, and ScienceDirect databases to obtain articles in all languages from January 2004 until July 2025. The primary outcome was risk of recurrent stroke during follow-up. Secondary outcomes were risk of new-onset atrial fibrillation (AF), all-cause mortality, and in-hospital complications. PROSPERO registration ID: CRD420250652870. Results: Only one RCT (post hoc evaluation of the DEFENSE-PFO trial) and 11 observational studies were included. In patients aged ⩾ 60 years, risk of recurrent stroke was lower when PFO was closed compared with ATA (5.48% vs 10.05%, respectively, hazard ratio (HR) = 0.56, 95% confidence interval (CI) = 0.45–0.80, p < 0.001, I 2 = 45.6%). All-cause mortality was also lower for PFO closure versus ATA (1.73% vs 7.59%, respectively, HR = 0.41; 95% CI = 0.19–0.90, p = 0.02; I 2 = 43.8%). There was no difference between PFO closure and ATA in risk of new-onset AF (HR = 1.13, 95% CI = 0.53–2.44, p = 0.74). Compared with patients < 60 years, individuals ⩾ 60 years who underwent PFO closure had a higher risk of recurrent stroke (2.94% vs 1.04%, respectively, HR = 3.47; 95% CI = 1.61–7.48; p = 0.001), new-onset AF (4.86% vs 1.01%, respectively, HR = 4.12; 95% CI = 1.90–8.95; p < 0.001), and all-cause mortality during follow-up (8.32% vs 0.39%, respectively, HR = 8.24; 95% CI = 3.49–19.46; p < 0.0001). In-hospital complications after PFO closure were comparable between two age groups. Due to insufficient data, we were not able to perform a subgroup analysis based on anatomic features of PFO, antithrombotic regimen, or occluder devices. Conclusion: Based on available data, which is predominantly derived from observational studies, PFO closure is associated with a reduced risk of recurrent stroke compared to ATA in patients over 60 years. However, these findings are subjected to limitations, including the potential for selection bias, unmeasured confounding, and insufficient long-term follow-up. Furthermore, long-term randomized trials are essential to definitively confirm efficacy and establish clinical guidelines for PFO closure in this older population.
The contribution of lumbar puncture opening pressure in the diagnosis of spontaneous intracranial hypotension: A systematic literature review and meta‐analysis
Parikh, Simy , Deline, Constance R., McCreary, Morgan , Amoozegar, Farnaz , Amrhein, Timothy J. , Carroll, Ian , Cutsforth‐Gregory, Jeremy K. , Leithe, Linda Gray, Kranz, Peter G. , Louy, Charles, Maya, M. Marcel , Rau, Jill C. , Silberstein, Stephen D., Schievink, Wouter I., Parikh, Simy , Amrhein, Timothy J , Carroll, Ian , McCreary, M , Kranz, Peter G , Moghekar, Abhay , Schievink, Wouter I. , Friedman, Deborah I.

Mayo Clinic

Headache: The Journal of Head and Face Pain | October 15, 2025 | Volume: 66 | Issue: 2 | Pages: 517-530

10.1111/head.15060 | PMID 41090555 Get It

Abstract Objective The objective of this study was to summarize the available evidence regarding the clinical value and trend over time of lumbar cerebrospinal fluid (CSF) opening pressure utilization to diagnose spontaneous intracranial hypotension (SIH). Background CSF opening pressure obtained via lumbar puncture is one of the diagnostic criteria for SIH based on the International Criteria for Headache Disorders, 3rd Edition (ICHD‐3), but it has questionable utility as an initial investigation for diagnosing SIH. Methods The authors performed a systematic literature review and meta‐analysis. PubMed/MEDLINE, Scopus, and Cochrane Library were searched from inception to October 2022. Original studies and case series in English reporting three or more patients with suspected or known SIH and CSF pressure measurement were included. Meta‐analyses and meta‐regression were used to calculate pooled estimates and examine the impact of age, sex, and publication year on outcomes, including CSF pressure < 60 mm CSF, orthostatic headache, and positive findings on brain magnetic resonance imaging (MRI), spinal imaging, and radionuclide studies. Results For every 1‐year increase in the year of publication, the odds of reporting low CSF pressure decreased by 6.20% (adjusted odds ratio [aOR] = 0.94, aOR 95% confidence interval [CI] = [0.90, 0.97], p = 0.001), the odds of reporting a positive brain MRI increased by 4.67% (aOR = 1.05, aOR 95% CI = [1.01, 1.09], p = 0.026), and the odds of reporting orthostatic headache increased by 9.13% (aOR = 1.09, aOR 95% CI = [1.03, 1.15], p = 0.002). Each 1% increase in the percentage of patients with orthostatic headache was associated with a 3.13% increase in the odds of low CSF pressure (aOR = 1.03, aOR 95% CI = [1.01, 1.05], p = 0.003). Similarly, as the percentage of patients with low CSF pressure increased by 1%, there was a 2.53% increase in the odds of orthostatic headache (aOR = 1.03, aOR 95% CI = [1.01, 1.04], p = 0.005). It was estimated that 31.9% of patients with SIH had normal opening pressure (95% CI = [24.0%, 40.8%], prediction interval = [5.0%, 80.5%]). Every 1% increase in the percentage of patients with positive brain MRI was associated with a 5.25% increase in the odds of positive spinal imaging (aOR = 1.05, aOR 95% CI = [1.00, 1.11], p = 0.047). Age and positive radionuclide study did not significantly impact the outcomes measured. The corresponding I 2 for each outcome was reduced by controlling for study‐wide covariates believed to impact the prevalence of each outcome. Sensitivity analyses did not reveal discrepancies in results when studies requiring outcomes of interest were removed. Conclusion Our analysis found that recent studies indicate a reduced reliance on opening pressure for diagnosing SIH. Rather, results suggest an increasing reliance on contrast‐enhanced brain MRI, spine imaging, and clinical features for SIH diagnosis.
Workload and Fairness: An Overdue Conversation About Clinical Faculty
Bradford, Paul , Hodgin, Faye C, McNicholl, Jenna, Min, Elana A. , Nandwana, Bindiya, McNicholl, Jenna, Strelow, Brittany

Mayo Clinic

The Journal of Physician Assistant Education | October 15, 2025 | Volume: 36 | Issue: 4 | Pages: 333-334

10.1097/jpa.0000000000000713 | PMID 41088512 Get It